Trials / Completed
CompletedNCT05059743
ADME Study of [14C]- Larotinib in Healthy Male Subjects
Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C] - Larotinib in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Sunshine Lake Pharma Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Study to Evaluate the Mass Balance and Biotransformation of Single Dose \[14C\]-Larotinib（Z650）in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-Larotinib | Patients will receive single dose of orally \[14C\]-Larotinib on Day 1. |
Timeline
- Start date
- 2021-11-20
- Primary completion
- 2022-01-10
- Completion
- 2022-01-10
- First posted
- 2021-09-28
- Last updated
- 2023-03-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05059743. Inclusion in this directory is not an endorsement.